Price (delayed)
$0.1801
Market cap
$16.19M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.48
Enterprise value
-$9.54M
Infinity Pharmaceuticals, Inc. ('Infinity' or the 'Company'), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of
There are no recent dividends present for INFI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.